Objectives: To assess the total systemic antiviral use in Europe and to identify the antiviral substances most commonly used.
Introduction
Comparisons of antibiotic, antifungal and antimycotic use in different European countries have been reported extensively by the European Surveillance of Antimicrobial Consumption (ESAC) project. 1 -6 However, data on the use of antivirals are scarce. Published information on antiviral use is mainly limited to single countries and single drugs, and is based on market or sales data using different denominators to express the use. 7 -10 In 2005, data on the consumption of antivirals were collected for the first time within the ESAC project, which was funded at that time by a grant from DG SANCO of the European Commission and is currently funded by the European Centre for Disease Prevention and Control (ECDC). ESAC is an international network of surveillance systems aiming to collect comparable and reliable data on antimicrobial use in Europe. 11 This article presents the first total (outand inpatient) systemic antiviral use data from 16 European countries in 2008. With regard to antiviral use for the prevention and/or treatment of influenza, these data could serve as a historical reference before the outbreak of the A/H1N1 pandemic.
Methods
In 2008, 36 countries participated in the ESAC project, including all 27 European Union (EU) member states, 4 applicant countries (Bulgaria, Croatia, Romania and Turkey), 3 of the 4 members of the European Free Trade Association (Iceland, Norway and Switzerland), Israel and Russia. ESAC collects data on antimicrobial use aggregated at the level of the active substance and according to the anatomical therapeutic chemical (ATC) classification and the defined daily dose (DDD) measurement unit (WHO, version 2010). 12 The ATC J05 class, dedicated to antivirals for systemic use, includes 57 unique substances (Table 1) . For four substances (J05AC02, J05AG02, J05AR05 and J05AX05), no DDD has been assigned by WHO, but to allow valid and comparable measurement of their use, an estimated theoretical daily dose was adopted during the ESAC annual meeting, held in June 2010 in Stockholm, Sweden, and included in Table S1 (available as Supplementary data at JAC Online). After this meeting, an extra validation for these four substances and also for antiviral combinations for the treatment of HIV infections (ATC J05AR) was requested. Only countries with validated data will be presented in this analysis.
Use was expressed in DDD per 1000 inhabitants per day (DID). The number of inhabitants in the participating countries was based on the midyear population in the country.
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All antiviral substances were grouped according to their main indication into seven categories (Table S1) , including: 'Influenza antivirals' (i.e. substances used for the treatment of influenza, ATC J05AC02 and J05AH); 'Hepatitis C antivirals' (i.e. substances used for the treatment of hepatitis C, ATC J05AB04); 'Herpes antivirals' (i.e. substances used for the treatment of herpetic infection, ATC J05AC03, J05AD01 and J05AB except J05AB04); 'HIV/AIDS antivirals' (i.e. substances used for the treatment of HIV/AIDS, ATC J05AE, J05AF01-04, J05AF06, J05AG, J05AR and J05AX07-09); and 'Hepatitis B antivirals' (i.e. substances used for the treatment of hepatitis B, ATC J05AF08 and J05AF10-12). Lamivudine (ATC J05AF05), tenofovir (ATC J05AF07) and emtricitabine (ATC J05AF09), used for both HIV and hepatitis B treatment, were labelled as 'HIV/hepatitis B antivirals' and grouped as a separate category to allow assessment of their relative contribution in each country when considered as part of HIV treatment or hepatitis B treatment. The remaining antivirals (ATC J05AA, J05AD02, J05AX01, J05AX02, J05AX05 and J05AX06) were labelled as 'Others'.
The correlation between substances used for the treatment of HIV/ AIDS patients (i.e. 'HIV/AIDS antivirals' and 'HIV/hepatitis B antivirals') and the number of HIV/AIDS patients was assessed using Spearman's coefficient for non-parametric correlation. For an estimation of the number of HIV/AIDS patients the cumulative total reported in the HIV/ AIDS surveillance report was used.
14 All P values were based on two-tailed tests of significance. A P value of ,0.05 was considered statistically significant. Statistical analysis was performed using SPSS software, version 15.0 for Windows (SPSS, Inc., Chicago, IL, USA). Data sources, validity of the data collection and details of the methodology used, as well as the associated problems, have been described and discussed in detail previously.
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Results
Total antiviral use data, i.e. out-and inpatient use, were collected from 12 countries (Belgium, Croatia, Denmark, Estonia, Finland, France, Hungary, Italy, Luxembourg, Russia, Slovenia and Sweden). In these countries the outpatient use ranged from 9.7% (Italy) to 98.3% (Sweden) of the total antiviral use. Antiviral use data were derived from reimbursement data in Austria, Belgium, Italy and Luxembourg and from distribution or sales data in the other countries (Table S2 , available as Supplementary For only 20 of the 57 substances assigned an ATC code, the use in 2008 represented more than 1% of the total antiviral use, while no use was recorded for 12 substances, including 2 substances with an estimated theoretical daily dose (Table 1) . Table 2 Total use of 'HIV/AIDS antivirals' represented 60.13% of the total antiviral use and varied by a factor of 162.11 between the country with the highest (2.43 DID in France) and the country with the lowest (0.02 DID in Russia) use. In all countries these substances represented more than 50% except in Finland (49.45%), Slovenia (40.49%), Hungary (14.58%) and Russia (2.55%).
Total use of 'HIV/hepatitis B antivirals' (lamivudine, tenofovir and emtricitabine) represented 12.39% of the total antiviral use and varied by a factor of 136.81 between the country with Figure S2 (available as Supplementary data at JAC Online). Aciclovir and valaciclovir were the most commonly used anti-herpetic drugs in all countries. Brivudine was used considerably in Luxembourg (18.47%), Slovenia (18.02%) and Italy (9.89%). The use of ganciclovir and valganciclovir was lower, ranging from 14.78% in Croatia to 0.25% in Russia. 
Discussion
We observed a striking variation of total systemic antiviral use in Europe. The variation factor between the country with the highest and lowest total antiviral use was more than twice that for systemic outpatient antibiotic use and 1.6 times that for systemic outpatient antimycotic and antifungal use. 5, 6 While for antibiotics, antimycotics and antifungals outpatient use represents at least 90% of the total use, for outpatient antiviral use the proportion ranges from 9.71% in Italy to 98.33% in Sweden. Therefore, we presented total antiviral use in the 12 countries under study separately from outpatient use in Austria, the Netherlands, Norway and Portugal.
The outpatient use pattern of Austria, the Netherlands and Norway is similar compared with the total use patterns, while for Portugal the pattern is completely different. This is probably explained by the exclusive distribution of substances for the treatment of chronic viral-infected patients (like AIDS, HIV and hepatitis B) by hospital pharmacies in Portugal, while for Austria, the Netherlands and Norway these substances are also distributed by public pharmacies.
We used an estimated theoretical daily dose for four substances without an official WHO DDD to allow a valid and comparable measurement of their use in Europe. These substances represented less than 5% of the total antiviral use. Regarding the ATC/DDD methodology, it also has to be taken into account that countries using combination products will have a lower absolute DID than countries using a combination of single substances, e.g. 1 DDD of J05AR02 (DDD ¼ 1 tablet containing 600 mg of abacavir and 300 mg of lamivudine) equals 2 DDD of the single substances abacavir (DDD¼ 600 mg) and lamivudine (DDD¼ 300 mg).
It is not clear whether large differences in antiviral use among European countries can be explained by similar determinants as for antibiotic, antimycotic and antifungal use (e.g. social-cultural differences, differences in education, healthcare organization, resources and utilization, pharmaceutical market DDD 50 000 000 60 000 000 70 000 000 4 000 000 6 000 000 8 000 000 10 000 000
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and regulatory practices, and knowledge on antimicrobials). For example, the Netherlands ranks among the lowest for per capita use of antibiotics, but also (with outpatient data only) has among the highest antiviral consumption. For a better understanding of this and other observations, grouping the antiviral substances into categories according to their main indication allowed a more clinically relevant description of their use. In most countries, substances used in HIV/AIDS treatment represented more than 50% of the total use, and therefore their use will strongly determine the variation between countries. The strong correlation between their use in DDD and the total number of HIV/AIDS patients (Figure 2a) suggests that these substances are indeed mainly used for HIV/AIDS treatment, that most registered HIV/AIDS patients will receive treatment and that the ESAC use data are valid. The number of HIV/AIDS patients actually treated will determine antiviral consumption. This consumption may vary considerably, as the population of HIV/AIDS patients typically consists of minority groups or even suppressed subcultures (e.g. drug users, homosexuals and immigrants). The Netherlands, among some other countries, has been trying to organize the care for these groups by an efficient nationwide programme that is fully reimbursed and rather successful, leading to higher consumption of antivirals. 15 Moreover, most antiviral substances to treat HIV-positive patients are used for several years, even decades, whereas antibiotics, antimycotics and antifungals are mainly used to treat incidental infections. In addition, with the increased prevalence of HIV infections and decreased mortality, we can expect a yearly increase in antiviral consumption.
However, despite international recommendations on antiretroviral therapy for HIV infection by the WHO, 16 differences in the relative use of antiviral classes can be observed. Differences in national guidelines for HIV/AIDS treatment and compliance with these guidelines may partially explain this variation, together with differences in reimbursement systems of antiviral classes between countries. Surveillance data on the prevalence of hepatitis B and C are difficult to compare across countries due to differences in system structures, reporting practices, data collection methods and case definitions. 17 -19 Moreover, for hepatitis B, the ESAC use data without links to indication do not allow for the assessment of use for hepatitis B without bias of the 'HIV/hepatitis B antivirals', which represent the major part in most countries in comparison with the 'Hepatitis B antivirals'.
Hepatitis C, however, is nearly universally treated with (peg)interferon in combination with ribavirin (J05AB04) for 6 months to 1 year. 20 This treatment is also applied in Croatia, but ribavirin is obtained through donation by pharmaceutical companies selling (peg)interferon, and therefore ribavirin use is not registered in the Croatian wholesale data. Monitoring ribavirin use could serve as an indicator of the prevalence of hepatitis C and help validate surveillance data. Alternatively, differences in compliance with recommended treatment strategies could be identified.
The intercountry variation in anti-herpetic substances is smaller compared with the other categories, but still considerable (factor 7.99). These substances are mainly used for the treatment or suppression of herpes simplex and herpes zoster infection and their variation can be explained by differences between national treatment guidelines, different reimbursement systems and drug cost. The use of ganciclovir and valganciclovir, indicated to treat cytomegalovirus, is less common, clearly For the prevention and/or treatment of influenza, Russia is the only country that reports extensive use of cyclic amines. Amantadine (ATC N04BB01), a cyclic amine originally developed for the treatment of early influenza A viral infection, is not included in the ESAC data. Amantadine is currently used in the treatment of Parkinson's disease and drug-induced extrapyramidal reactions, as well as off-label use in combating the fatigue associated with multiple sclerosis. Amantadine is no longer recommended for the treatment or prevention of influenza, but it might still be used for this indication. For example, in Norway, amantadine is only reimbursed for chronic infections. However, less than half of the sold DDDs were reimbursed, suggesting amantadine is used for other indications, such as influenza. Data linking prescriptions with indication are necessary to reveal actual use. In the meantime, we suggest including amantadine in the antiviral database. The use of neuraminidase inhibitors is not particularly widespread, representing 4.5% in Finland to 0.02% in Luxembourg. In Belgium and Portugal, oseltamivir and zanamivir are not reimbursed, and for that reason they are not included in the data. Quarterly data covering several years rather than calendar years will be helpful in interpreting the use of antivirals for the prevention and/or treatment of influenza.
During the outbreak of the A/H1N1 pandemic in 2009, stockpiles of neuraminidase inhibitors, primarily oseltamivir, were used to provide primary healthcare professionals with neuraminidase inhibitors for distribution without prescription in Belgium. Several European countries also had a stock of oseltamivir already purchased, e.g. in 2005 during the avian flu pandemic. 21, 22 Stockpiling and distribution without prescription might represent an important obstacle to monitoring actual antiviral consumption. In countries providing reimbursement data (Austria, Belgium, Hungary, Italy and Luxembourg) and countries providing sales data from community pharmacists (the Netherlands and Sweden), the use of stockpiles and distribution without prescription by primary healthcare professionals are not monitored. In countries providing distribution data (Denmark, Finland, France, Norway and Slovenia), stockpiles can be monitored, but these do not necessarily reflect actual consumption.
We have shown that differences in outpatient antibiotic selection pressure account for geographical variation of antibiotic resistance in Europe.
3 However, antiviral resistance, except for HIV and hepatitis B virus, has only been reported in specific patient groups (e.g. in immunocompromised patients) and has not been reported to spread in the community. 7 HIV treatment may well induce resistance, but this is largely a problem in individual patients who receive suboptimal treatment regimens, although such resistance can also, to some extent, be transmitted. In addition, resistance sometimes appears to occur unrelated to antiviral consumption, as observed with the influenza drugs amantadine and oseltamivir (2007 -08 H1N1). 23 -26 In conclusion, the ESAC project represents the first set of publicly available standardized and validated supranational data on systemic antiviral use in Europe. The variation is mainly determined by the use of HIV/AIDS antivirals. These observations should stimulate further analysis of the variation of specific antiviral substances. ESAC data will facilitate auditing of antiviral prescribing and evaluation of the implementation of guidelines and public health policies.
